SCHEMBL9937386

SCHEMBL9937386

CCCCOC(=O)NNCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 3/20 0.47
HDAC1 Q13547 3/20 0.47
TSHR P16473 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HDAC3 O15379 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC8 Q9BY41 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2A1 P68400 1/20 0.44
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473103 0.92 TDP1 (0.55) SMN1; SMN2CYP1A2CYP2C19TDP1TSHR
SCHEMBL15285491 0.87 MMEL1 (0.52) RAB9ALMNA
SCHEMBL474570 0.86 SMN1; SMN2 (0.53) SMN1; SMN2CYP1A2CYP2C19TDP1TSHR
SCHEMBL14919094 0.83 MGLL (0.45) SMN1; SMN2CYP1A2CYP2C19HDAC1TSHR
SCHEMBL27669569 0.78 LMNA (0.51) SMN1; SMN2CYP1A2CYP2C19HDAC1TSHR
SCHEMBL10436016 0.78 HDAC3 (0.56) SMN1; SMN2CYP1A2CYP2C19TDP1HDAC1
SCHEMBL3806762 0.77 EPHX2 (0.56) SMN1; SMN2CYP1A2CYP2C19TDP1TSHR
SCHEMBL9936982 0.76 MME (0.61)
SCHEMBL15201783 0.76 MME (0.61)
SCHEMBL7434407 0.76 GAA (0.60) SMN1; SMN2CYP1A2CYP2C19TDP1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651900-A1 NEPRILYSIN INHIBITORS Theravance, Inc. (US) 2013-10-23 EP disclosed
WO-2012082857-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-06-21 WO disclosed